Table 1

Overall clinical and biological parameters of 55 obese subjects and 15 lean controls

Phenotype

Obese subjects

Lean controls


n

55

15

Female/Male

52/3

15/0

Age (years)

40.13 ± 11.67

34.2 ± 8.52

BMI (kg/m2)

44.07 ± 9.06*

23.67 ± 1.51

Glucose homeostasis

Glucose (mmol/l)

5.56 ± 1.70

4.82 ± 1.01

Insulin (μU/ml)

13.51 ± 8.57

7.20 ± 3.49

QUICKI

0.33 ± 0.05

0.36 ± 0.04

Type 2 diabetes

Glycemia > 7 mmol/l or treatment

6 (11%)

0

Lipid homeostasis

Cholesterol (mmol/l)

5.22 ± 1.04

4.36 ± 1.05

HDL cholesterol (mmol/l)

1.27 ± 0.34

1.43 ± 0.23

Triglycerides (mmol/l)

1.40 ± 0.62

0.45 ± 0.10

Adipokines

Leptin (ng/ml)

54.55 ± 19.92

11.24 ± 1.12

Adiponectin (μg/ml)

7.14 ± 2.87

-

Risk factors

HDL < 1.03 mmol/l (M), < 1.29 mmol/l (F)

26 (47%)*

1 (6%)

Hypertension ≥ 130/85 mmHg

11 (20%)

0

Glucose ≥ 5.6 mmol/l

17 (31%)

1 (6%)

Triglycerides ≥ 1.7 mmol/l

11 (20%)

0

Inflammatory factors

TNF-α (pg/ml)

1.77 ± 0.62

-

IL6 (pg/ml)

2.24 ± 1.17

-

hsCRP (mg/dl)

8.62 ± 10.38

-

Orosomucoid (g/l)

0.99 ± 0.18

-

Serum amyloid A (μg/ml)

21.35 ± 22.39

-

Hepatic factors

Aspartate aminotransferase (IU/l)

22.66 ± 6.87

-

Alanine aminotransferase (IU/l)

35.72 ± 18.56

-

γGT (mg/dl)

45.91 ± 46.43

-


*Bilateral significance p value < 0.05 for the difference between the two groups. Bilateral significance p value < 0.001 for the difference between the two groups. Hyphens indicate parameters that were not available for the lean controls group. F, female; HDL, high-density lipoproteins; M, male.

Henegar et al. Genome Biology 2008 9:R14   doi:10.1186/gb-2008-9-1-r14

Open Data